Loading viewer...
earnings
Format: PDF earnings
Ascelia Pharma presented its H1 2024 results highlighting the successful completion of Phase 3 clinical development for Orviglance®. The presentation covers quarterly financial performance, recent milestones, and the company's pipeline strategy in orphan oncology focused on delivering targeted cancer treatments.
earnings
12 Pages
Unknown
Wheels Up Q1 2023 Earnings Presentation
earningsearnings
15 Pages
Wheels Up Experience Inc.